Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 329 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mesenchymal stem cells Clear all
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 5:47 AM EDT
Active, not recruiting Phase 1 Interventional

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

NCT05820711
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
MSC
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 24, 2026, 5:47 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

NCT05157958
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
ALLO-ASC-SHEET, Vehicle Control
Biological · Other
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
4 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 24, 2026, 5:47 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT05167721
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Autologous Mesenchymal Stem Cells, Placebo
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

NCT03929120
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Diseases
Interventions
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 24, 2026, 5:47 AM EDT
Terminated Phase 1 Interventional

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

NCT01751282
View directory record Official record
Conditions
Non Healing Wounds
Interventions
Stem Cell
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 24, 2026, 5:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

MSC EVs in Dystrophic Epidermolysis Bullosa

NCT04173650
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
AGLE-102
Drug
Lead sponsor
Aegle Therapeutics
Industry
Eligibility
6 Months and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

NCT02412735
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture, Placebo
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 24, 2026, 5:47 AM EDT
Not listed Phase 1 Interventional

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 24, 2026, 5:47 AM EDT
Terminated Phase 1 Interventional

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

NCT02675556
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Allo-hMSCs, Placebo
Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous mesenchymal stem cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Stem Cell Therapy to Improve Burn Wound Healing

NCT02104713
View directory record Official record
Conditions
Skin Burn Degree Second
Interventions
Allogeneic (MSC's) Application to the Burn Wounds
Biological
Lead sponsor
E.Badiavas
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 24, 2026, 5:47 AM EDT
Withdrawn Not applicable Interventional

The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers

NCT00815217
View directory record Official record
Conditions
Diabetic Wounds, Venous Stasis Wounds
Interventions
injection of lipoaspirate, control
Procedure · Other
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 24, 2026, 5:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for Age-Related Frailty

NCT05284604
View directory record Official record
Conditions
Frailty
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 1 Interventional

Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation

NCT00186914
View directory record Official record
Conditions
Osteodysplasia
Interventions
Marrow stromal cell infusion
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 24, 2026, 5:47 AM EDT
Recruiting Phase 1 Interventional

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Autism

NCT05003960
View directory record Official record
Conditions
Autism
Interventions
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 5:47 AM EDT
Not yet recruiting No phase listed Observational

Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury

NCT07326059
View directory record Official record
Conditions
Traumatic Brain Injury, Traumatic Brain Injury (TBI) Patients, Traumatic Brain Injury (TBI); Concussion, Initial Encounter, Traumatic Brain Injury (TBI); Concussion, Subsequent Encounter, Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With Persistent Cognitive Deficits
Interventions
MUSE Stem Cell Therapy
Biological
Lead sponsor
Healing Hope International
Other
Eligibility
6 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 24, 2026, 5:47 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

NCT01297413
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Allogeneic adult mesenchymal bone marrow stem cells
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
Gilbert, Arizona • Orange, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 24, 2026, 5:47 AM EDT
Available No phase listed Expanded access

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

NCT07238062
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 85 Years
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 24, 2026, 5:47 AM EDT
Not listed Phase 1Phase 2 Interventional

Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

NCT03525418
View directory record Official record
Conditions
HLHS
Interventions
Longeveron Mesenchymal Stem Cells
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
1 Day to 1 Year
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 24, 2026, 5:47 AM EDT
Withdrawn Phase 2 Interventional

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

NCT01770613
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
Interventions
Stem cells
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Gilbert, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 24, 2026, 5:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 24, 2026, 5:47 AM EDT